Hematopoietic stem cell transplantation in multiple myeloma.
High-dose therapy and autologous hematopoietic stem cell transplantation are standard early treatment of patients with multiple myeloma. Tandem transplantation appears to provide additional benefit, particularly in patients with limited response to initial transplantation. Myeloablative allogeneic transplantation provides the only potential for cure, but has been largely abandoned because of high mortality rates. Newer and better induction regimens, rigorous analysis of results with autologous and allogeneic transplantation, and the development of risk-adapted stratification provide the impetus for this critical evaluation of the role of hematopoietic stem cell transplantation in multiple myeloma.
Pant
Shubham
S
Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 44195, USA.
Copelan
Edward A
EA
D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D018183:Transplantation Chimera; D014182:Transplantation, Autologous / Q000379:methods; D014184:Transplantation, Homologous / Q000379:methods